ST1968 Intravenous (Weekly) in Solid Tumors

Inclusion Criteria: * Histological/cytological diagnosis of solid tumors for which therapy of proven efficacy does not exist. * Preferably measurable disease * ECOG performance status ≤ 1. * Age ≥ 18 years. * Ongoing toxicity associated with prior anticancer therapy ≤ grade 1 (NCI-CTCAE V3.0). * Maximum of 2 prior chemotherapy lines for advanced disease (not including neoadjuvant or adjuvant chemotherapy) * Adequate hematological, liver and renal function * Hemoglobin ≥ 9 g/dl; ANC ≥ 1.5 x 109/L; platelets ≥ 100 x 109/L; * Serum bilirubin ≤ upper normal limit (UNL). ALT, AST ≤ UNL but ≤ 2.5 x UNL in case of liver metastases; alkaline phosphatase (liver isoenzyme fraction) ≤ UNL or ≤ 1.5xULN in case of liver metastases; albumin within normal limits; * Creatinine ≤1.5 mg/dl or calculated creatinine clearance ≥ 60 ml/min. * Life expectancy of at least 3 months * Capacity of understanding the nature of the trial and giving written informed consent. Exclusion Criteria: * Less than 4 weeks since last chemotherapy, radiotherapy or prior investigational therapy. Less than 2 weeks since last hormone or immunotherapy or signal transduction therapy. * Active infection. * Presence of cirrhosis or chronic hepatitis * Presence of serious cardiac (congestive heart failure, angina pectoris, myocardial infarction within one year prior to study entry, uncontrolled hypertension or arrhythmia), neurological or psychiatric disorder. * Presence of uncontrolled intercurrent illness or any condition which in the judgement of the investigator would place the subject at undue risk or interfere with the results of the study. * Symptomatic brain metastases (this does not include primary brain tumors) or leptomeningeal disease. * Pregnancy or lactation or unwillingness to use adequate method of birth control